I totally agree with thefamilyman. IMO BP would not bring anything to the table for B-CV19 that the U.S. government can not provide. What does BP provide IPIX in regards to CV19 that would justify giving them 85% of Brilacidin revenue? Without having a middleman (BP) taking a lion's share of the profit, Leo will have much more pricing flexibility. My guess is that Remdesivir has set the pricing bar. If Brilacidin performs at a similar efficacy in human trials as proven in labs (80% more effective in viral reduction as Remdesivir) and Leo decides to price below Remdesivir it will be a no-brainer for the U.S. government to endorse Brilacidin as the top CV19 treatment.